Quarterly Focus Issue: Heart FailureClinical ResearchDifferences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease: A Randomized Crossover Trial
Key Words
Abbreviations and Acronyms
Cited by (0)
This study was supported by an unrestricted education grant (“Cardiovascular Lipid” Grant) from Pfizer Australia(West Ryde, New South Wales, Australia) to the principal investigator Assoc. Prof. Hayward. The funding source had no role in the design, conduct, data analysis, or reporting of this study or in the decision to submit the manuscript for publication. Dr. Jabbour has received minor honoraria and educational financial support from AstraZeneca, Roche, and Alpha-Pharma. Dr. Macdonald has received speaker fees from AstraZeneca, Actelion Janssen-Cilag, Novartis, and Pfizer. Dr. Keogh has received trial funding from Actelion, Myogen, Gilead, Pfizer, GlaxoSmithKline, Venragr, Heartware, Novartis, Roche, Bayer, and Schering. Dr. Kotlyar has received honoraria for speaking engagements from Alpha-Pharma and AstraZeneca. Dr. Krum has received grant funding from Roche, Alpha-Pharma, and Merck CSL. Assoc. Prof. Hayward has received grant funding from Pfizer, and honoraria/travel grants from AstraZeneca, Roche, and Alpha-Pharma, CSL Biotherapies, and Merck.